Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Martha A. MaloneyHuss"'
Autor:
M. Kazim Panjwani, Matthew J. Atherton, Martha A. MaloneyHuss, Kumudhini P. Haran, Ailian Xiong, Minnal Gupta, Irina Kulikovsaya, Simon F. Lacey, Nicola J. Mason
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
Multiple rodent and primate preclinical studies have advanced CAR T cells into the clinic. However, no single model accurately reflects the challenges of effective CAR T therapy in human cancer patients. To evaluate the effectiveness of next-generati
Externí odkaz:
https://doaj.org/article/d7afee87aa414d559adb4c116f51da3a
Autor:
Guannan Wang, Ming Wu, Martha A Maloneyhuss, John Wojcik, Amy C Durham, Nicola J Mason, David B Roth
Publikováno v:
PLoS ONE, Vol 12, Iss 11, p e0188667 (2017)
Angiosarcomas (AS) are rare in humans, but they are a deadly subtype of soft tissue sarcoma. Discovery sequencing in AS, especially the visceral form, is hampered by the rarity of cases. Most diagnostic material exists as archival formalin fixed, par
Externí odkaz:
https://doaj.org/article/7ac3c875436445e4b9d74081a70e7cae
Autor:
Glenna E. Mauldin, Sridhar M Veluvolu, Dorothy Cimino Brown, Martha A. MaloneyHuss, Erika L. Krick
Publikováno v:
Journal of Feline Medicine and Surgery. 22:299-304
Objectives The aims of this study were to evaluate the safety of mustargen, vincristine, procarbazine and prednisone (MOPP) chemotherapy in the treatment of relapsed or refractory feline lymphoma, and to determine the overall response rate and median
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32d408173a8c23c89811baccbb7d5498
https://doi.org/10.1177/1098612x19841916
https://doi.org/10.1177/1098612x19841916
Autor:
M. Kazim Panjwani, Matthew J. Atherton, Minnal Gupta, Nicola J. Mason, Irina Kulikovsaya, Kumudhini Preethi Haran, Ailian Xiong, Martha A. MaloneyHuss, Simon F. Lacey
Publikováno v:
Oncoimmunology
OncoImmunology, Vol 9, Iss 1 (2020)
OncoImmunology, Vol 9, Iss 1 (2020)
Multiple rodent and primate preclinical studies have advanced CAR T cells into the clinic. However, no single model accurately reflects the challenges of effective CAR T therapy in human cancer patients. To evaluate the effectiveness of next-generati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e5dd1bb4b568de4d2a280e3567905be
http://europepmc.org/articles/PMC6959441
http://europepmc.org/articles/PMC6959441
Autor:
Martha A. MaloneyHuss, Amy C. Durham, John Wojcik, Ming Wu, Nicola J. Mason, David Roth, Guannan Wang
Publikováno v:
PLoS ONE, Vol 12, Iss 11, p e0188667 (2017)
PLoS ONE
PLoS ONE
Background Angiosarcomas (AS) are rare in humans, but they are a deadly subtype of soft tissue sarcoma. Discovery sequencing in AS, especially the visceral form, is hampered by the rarity of cases. Most diagnostic material exists as archival formalin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e7b8211a41c42befb486b9447329ea1
https://doi.org/10.1371/journal.pone.0188667
https://doi.org/10.1371/journal.pone.0188667
Publikováno v:
Molecular Therapy. 24:S296
Chimeric antigen receptor (CAR) T cell therapy has shown great promise in treating human leukemias. However, for CAR T technology to achieve its full potential against solid malignancies, better pre-clinical models are needed that recapitulate the im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0cc415360235411fec978d63aeba1b58
https://doi.org/10.1016/s1525-0016(16)33558-4
https://doi.org/10.1016/s1525-0016(16)33558-4
Publikováno v:
The Journal of Immunology. 196:214.9-214.9
Chimeric antigen receptor (CAR) therapy has demonstrated great promise in treating human leukemias, but preclinical murine models are limited in their ability to predict safety and efficacy in humans. Given the rapid and on-going advances in CAR T ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d85af492d04680b5ef6aeafedc9e4025
https://doi.org/10.4049/jimmunol.196.supp.214.9
https://doi.org/10.4049/jimmunol.196.supp.214.9